双边威尔姆斯瘤对化疗的反应表明组织学亚型,并指导治疗
Colton Duncan1, Suraj Sarvode Mothi2, Teresa C Santiago3
1Departments of Surgery, St Jude Children's Research Hospital, Memphis, TN, USA.
Journal of the National Cancer Institute
|March 28, 2024
概括
在化疗期间生长的双边威尔姆斯瘤往往是 stromal 主导的,特别是在幼儿中. 这表明,在这些情况下,优先考虑手术而不是活检,以保持功能.
科学领域:
- 儿科瘤学 儿科瘤学
- 腎臟病學 (nephrology) 是一種醫學.
- 手术瘤学手术瘤学
背景情况:
- 双边威尔姆斯瘤治疗包括新辅助化疗,在手术前缩小瘤.
- 活检有时用于反应不良的瘤,以指导治疗调整.
- 了解化疗反应可以优化治疗策略,并可能避免侵入性手术.
研究的目的:
- 研究双边威尔姆斯瘤中初始化疗反应和瘤组织学之间的关联.
- 为了确定在新辅助化疗期间的瘤生长是否预测特定的组织学亚型.
- 通过将临床反应与瘤特征相关联,为治疗决策提供信息.
主要方法:
- 对68名同步双边威尔姆斯瘤患者的回顾性分析,这些患者在一个机构接受治疗 (2000-2022年).
- 利用混合效应的后勤回归模型来评估基于化疗反应的肌主导组织学的可能性.
- 评估瘤大小变化和诊断时的患者年龄作为预测因素.
主要成果:
- 在新辅助化疗期间,瘤的增大显示出具有显著更高的 stromal 主导的几率 (OR=19.5).
- 患有 stromal 主导瘤的患者在诊断时最年轻 (平均18.8个月).
- 瘤生长和年龄在18个月以下的组合预测了以85.7%的准确性预测了 stromal 主导的组织学.
结论:
- 在新辅助化疗期间瘤体积的增加强烈暗示着侧膜主导的双边威尔姆斯瘤,特别是在18个月以下的患者中.
- 应该考虑继续进行脏节约手术,而不是为此类瘤进行活检.
- 这种方法可以帮助避免不必要的活检或改变化疗方案,优化患者的护理.
更多相关视频
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
1.9K
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
8.2K
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
